Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.10 per share
-
Shares outstanding
-
1.15B
-
Number of holders
-
644
-
Total 13F shares, excl. options
-
588M
-
Shares change
-
+12.3M
-
Total reported value, excl. options
-
$19.5B
-
Value change
-
+$427M
-
Put/Call ratio
-
1.59
-
Number of buys
-
286
-
Number of sells
-
-319
-
Price
-
$33.22
Significant Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) as of Q2 2017
790 filings reported holding TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share as of Q2 2017.
TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) has 644 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 588M shares
of 1.15B outstanding shares and own 51.27% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (76.3M shares), FRANKLIN RESOURCES INC (66.8M shares), FMR LLC (42.8M shares), BARROW HANLEY MEWHINNEY & STRAUSS LLC (30M shares), BlackRock Inc. (27.5M shares), WELLINGTON MANAGEMENT GROUP LLP (24.4M shares), HIGHFIELDS CAPITAL MANAGEMENT LP (21.4M shares), Bank of New York Mellon Corp (18.2M shares), Northern Cross, LLC (17.8M shares), and Invesco Ltd. (14.7M shares).
This table shows the top 644 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.